RayKnowChina Research Map
Shortlist

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病B-ALL

A leukaemia or lymphoma of immature B cells, found mainly in children and adolescents, with a high number of lymphoblasts. It most often appears as leukaemia.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
88

with a paper from 2016–2025 or a registered study

cities
37

where those hospitals are

open trials in China
89

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 23% of the world's English-language research papers on B-cell acute lymphoblastic leukaemia, 2021–2025 (12% in 2016–2020), and 16% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

88 hospitals in 37 cities

Order: papers led on B-cell acute lymphoblastic leukaemia, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 2 papers or 1 trial on B-cell acute lymphoblastic leukaemia, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing10
  2. Shanghai9
  3. Guangzhou8
  4. Changsha4
  5. Shenzhen4
  6. Xi'an4
  7. Hefei3
  8. Nanjing3
  9. Tianjin3
  10. Wuhan3

Each opens B-cell acute lymphoblastic leukaemia in that city. 27 more cities are in the menu below.

  1. 19 papers led
  2. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

    中国医学科学院血液病医院(血液学研究所)Tianjin

    13 papers led
  3. 12 papers led
  4. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    11 papers led
  5. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    8 papers led
    No open trial led
  6. Shanghai Children's Medical Center

    上海交通大学医学院附属上海儿童医学中心Shanghai

    8 papers led
  7. Hebei Yanda Lu Daopei Hospital

    河北燕达陆道培医院Langfang

    7 papers led
    No open trial led
  8. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    7 papers led
  9. 5 papers led
    No open trial led
  10. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    5 papers led
  11. 4 papers led
    No open trial led
  12. 4 papers led
    No open trial led
  13. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    4 papers led
    No open trial led
  14. 4 papers led
    No open trial led
  15. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    4 papers led
    No open trial led
  16. Xiangya Hospital

    中南大学湘雅医院Changsha

    4 papers led
    No open trial led
  17. 3 papers led
    No open trial led
  18. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    3 papers led
    No open trial led
  19. 3 papers led
    No open trial led
  20. 3 papers led
    No open trial led
  21. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    3 papers led
  22. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    3 papers led
    No open trial led
  23. 2 papers led
    No open trial led
  24. 2 papers led
    No open trial led
  25. 2 papers led
    No open trial led
  26. 2 papers led
    No open trial led
  27. 2 papers led
  28. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    2 papers led
    No open trial led
  29. 2 papers led
    No open trial led
  30. 2 papers led
    No open trial led
  31. 2 papers led
    No open trial led
  32. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    2 papers led
    No open trial led
  33. Tianjin First Central Hospital

    天津市第一中心医院Tianjin

    2 papers led
    No open trial led
  34. West China Second University Hospital

    四川大学华西第二医院Chengdu

    2 papers led
    No open trial led
  35. 1 paper led
    No open trial led
  36. Beijing Boren Hospital

    北京高博博仁医院Beijing

    1 paper led
    No open trial led
  37. 1 paper led
    No open trial led
  38. 1 paper led
    No open trial led
  39. 1 paper led
    No open trial led
  40. 1 paper led
    No open trial led
  41. 1 paper led
    No open trial led
  42. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    1 paper led
  43. 1 paper led
  44. 1 paper led
    No open trial led
  45. 1 paper led
    No open trial led
  46. 1 paper led
    No open trial led
  47. 1 paper led
    No open trial led
  48. Wuhan Children's Hospital

    武汉市儿童医院Wuhan

    1 paper led
    No open trial led
  49. Xijing Hospital

    空军军医大学西京医院Xi'an

    1 paper led
    No open trial led
  50. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    1 paper led
  51. 0 papers led
  52. 0 papers led
  53. 0 papers led
    No open trial led
  54. 0 papers led
  55. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    0 papers led
  56. 0 papers led
    No open trial led
  57. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    0 papers led
  58. 0 papers led
    No open trial led
  59. 0 papers led
  60. 0 papers led
  61. 0 papers led
    No open trial led
  62. 0 papers led
    No open trial led
  63. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    0 papers led
    No open trial led
  64. 0 papers led
    No open trial led
  65. 0 papers led
    No open trial led
  66. Health Hospital

    昆明霍普禾森医院Kunming

    0 papers led
    No open trial led
  67. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    0 papers led
    No open trial led
  68. 0 papers led
    No open trial led
  69. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    0 papers led
  70. 0 papers led
    No open trial led
  71. Northwest Women's Hospital

    西北妇女儿童医院Xi'an

    0 papers led
    No open trial led
  72. 0 papers led
    No open trial led
  73. 0 papers led
    No open trial led
  74. Pu'er People's Hospital

    普洱市人民医院Pu'er

    0 papers led
  75. 0 papers led
    No open trial led
  76. 0 papers led
    No open trial led
  77. 0 papers led
    No open trial led
  78. Shanghai General Hospital

    上海市第一人民医院Shanghai

    0 papers led
    No open trial led
  79. 0 papers led
    No open trial led
  80. 0 papers led
    No open trial led
  81. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    0 papers led
    No open trial led
  82. 0 papers led
    No open trial led
  83. 0 papers led
  84. 0 papers led
  85. Tongji Hospital

    同济大学附属同济医院Shanghai

    0 papers led
  86. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    0 papers led
    No open trial led
  87. Yan'an Hospital

    昆明市延安医院Kunming

    0 papers led
    No open trial led
  88. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    0 papers led
    No open trial led

By university or health system 41

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    20 papers led
    3 hospitals
  2. Peking University Health Science Center

    北京大学医学部Beijing

    19 papers led
    1 hospital
  3. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    15 papers led
    2 hospitals
  4. Soochow University

    苏州大学Suzhou

    15 papers led
    2 hospitals
  5. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    11 papers led
    3 hospitals
  6. Sun Yat-sen University

    中山大学Guangzhou

    10 papers led
    5 hospitals
  7. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    10 papers led
    2 hospitals
  8. Southern Medical University

    南方医科大学Guangzhou

    9 papers led
    2 hospitals
  9. Central South University (Xiangya)

    中南大学湘雅Changsha

    7 papers led
    3 hospitals
  10. Capital Medical University

    首都医科大学Beijing

    5 papers led
    2 hospitals
  11. Fujian Medical University

    福建医科大学Fuzhou

    5 papers led
    1 hospital
  12. Anhui Medical University

    安徽医科大学Hefei

    4 papers led
    1 hospital
  13. Guizhou Medical University

    贵州医科大学Guiyang

    4 papers led
    1 hospital
  14. Air Force Medical University

    空军军医大学Xi'an

    3 papers led
    1 hospital
  15. Army Medical University

    陆军军医大学Chongqing

    3 papers led
    1 hospital
  16. Chongqing Medical University

    重庆医科大学Chongqing

    3 papers led
    3 hospitals
  17. Guangzhou Medical University

    广州医科大学Guangzhou

    3 papers led
    2 hospitals
  18. Harbin Medical University

    哈尔滨医科大学Harbin

    3 papers led
    2 hospitals
  19. Nanjing Medical University

    南京医科大学Nanjing

    3 papers led
    2 hospitals
  20. Sichuan University (West China)

    四川大学华西Chengdu

    3 papers led
    2 hospitals
  21. China Medical University (Shenyang)

    中国医科大学Shenyang

    2 papers led
    1 hospital
  22. Jinan University

    暨南大学Guangzhou

    2 papers led
    2 hospitals
  23. Nanchang University

    南昌大学Nanchang

    2 papers led
    2 hospitals
  24. Shandong First Medical University

    山东第一医科大学Jinan

    2 papers led
    1 hospital
  25. Shandong University

    山东大学Jinan

    2 papers led
    1 hospital
  26. Shenzhen University

    深圳大学Shenzhen

    2 papers led
    2 hospitals
  27. Southwest Medical University

    西南医科大学Luzhou

    2 papers led
    1 hospital
  28. Tianjin Medical University

    天津医科大学Tianjin

    2 papers led
    1 hospital
  29. Wenzhou Medical University

    温州医科大学Wenzhou

    2 papers led
    1 hospital
  30. Xuzhou Medical University

    徐州医科大学Xuzhou

    2 papers led
    1 hospital
  31. Zhengzhou University

    郑州大学Zhengzhou

    2 papers led
    2 hospitals
  32. Qingdao University

    青岛大学Qingdao

    1 paper led
    1 hospital
  33. 1 paper led
    1 hospital
  34. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    0 papers led
    0 hospitals
  35. Fudan University

    复旦大学Shanghai

    0 papers led
    0 hospitals
  36. Guangdong Medical University

    广东医科大学Zhanjiang

    0 papers led
    0 hospitals
  37. Jilin University

    吉林大学Changchun

    0 papers led
    0 hospitals
  38. Kunming Medical University

    昆明医科大学Kunming

    0 papers led
    0 hospitals
  39. Tongji University

    同济大学Shanghai

    0 papers led
    0 hospitals
  40. Xi'an Jiaotong University

    西安交通大学Xi'an

    0 papers led
    0 hospitals
  41. Xiamen University

    厦门大学Xiamen

    0 papers led
    0 hospitals

89

open trials on B-cell acute lymphoblastic leukaemia in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 73 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT06326008

    Age 1 year to 18 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  2. Recruiting
    KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07246707

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2026-02
    Registry
    NCT07429461

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07470073

    Age 12 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  5. Recruiting
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07575919

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  6. Recruiting
    Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07575971

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  7. Recruiting
    Phase I Study of FXS0683 in the Treatment of Blood Tumors
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07616089

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  8. Recruiting
    Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07838714

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  9. Recruiting
    BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07854652

    Age 14 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  10. Recruiting
    GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-08
    Registry
    NCT07910708

    Age 18 years to 75 years (registered criteria)

    Led by Pu'er People's HospitalPu'er

  11. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06481735

    Age 16 years to 70 years (registered criteria)

    Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin

  12. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06689917

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  13. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  14. Recruiting
    Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06793241

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  15. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  16. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06890065

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  17. Recruiting
    Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06890494

    Age 18 years to 70 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  18. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT06940960

    Age 12 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  19. Recruiting
    Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06961669

    Age 3 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  20. Recruiting
    Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06985485

    Age 15 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  21. Recruiting
    Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07003737

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  22. Recruiting
    BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07008885

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  23. Recruiting
    CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07072494

    Age 14 years to 80 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  24. Recruiting
    Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07105579

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  25. Recruiting
    CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07106749

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  26. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  27. Recruiting
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
    Phase
    Early phase 1
    Started
    2025-09
    Registry
    NCT07205315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  28. Recruiting
    Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT07244406

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  29. Recruiting
    CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07441291

    Age 3 years to 79 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  30. Recruiting
    Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07564453

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  31. Recruiting
    Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07763054

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Central South UniversityHaikou

  32. Recruiting
    Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06060782

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  33. Recruiting
    CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06179524

    Age Not stated to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  34. Recruiting
    RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06250959

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  35. Recruiting
    The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-03
    Registry
    NCT06307600

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan

  36. Recruiting
    Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06343090

    Age 1 year to 70 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  37. Recruiting
    CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
    Phase
    Early phase 1
    Started
    2024-05
    Registry
    NCT06346912

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  38. Recruiting
    CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06355739

    Age 3 years to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  39. Recruiting
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06387121

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  40. Recruiting
    CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06389305

    Age 1 year to 39 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  41. Recruiting
    Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06393985

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  42. Recruiting
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06445803

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai

  43. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  44. Recruiting
    Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06481228

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  45. Recruiting
    Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06481241

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  46. Recruiting
    Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
    Phase
    Phase 1
    Started
    2024-04
    Registry
    NCT06507514

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  47. Recruiting
    Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06554626

    Age 40 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  48. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

  49. Recruiting
    Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06581081

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  50. Recruiting
    Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Registry
    NCT06607419

    Age 1 month to 18 years (registered criteria)

    Led by Shanghai Children's Medical Center; 1 listed hospital as study siteHefei, Shanghai

  51. Recruiting
    Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06608732

    Age 16 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  52. Recruiting
    Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06696833

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  53. Recruiting
    Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06718244

    Age 16 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  54. Recruiting
    CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06735495

    Age 3 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  55. Recruiting
    Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06742515

    Age 15 years to 59 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  56. Recruiting
    CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06752785

    Age 1 year to 18 years (registered criteria)

    Led by Guangzhou Women and Children's Medical CenterGuangzhou

  57. Recruiting
    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06754267

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  58. Recruiting
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06880913

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  59. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  60. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT06927466

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

  61. Recruiting
    Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT07584889

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  62. Recruiting
    Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT07677878

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  63. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

  64. Recruiting
    Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
    Phase
    Phase 4
    Started
    2023-09
    Registry
    NCT06339775

    Age Not stated to 65 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  65. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2023-09
    Registry
    NCT06678282

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  66. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

  67. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  68. Recruiting
    CAV Regimen for R/R Ph- B-ALL
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05657652

    Age 15 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  69. Recruiting
    CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT06081478

    Age 14 years to 85 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  70. Recruiting
    Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
    Phase
    Phase 2
    Started
    2021-12
    Registry
    NCT05088226

    Age 12 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  71. Recruiting
    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
    Phase
    Early phase 1
    Started
    2020-01
    Registry
    NCT04227015

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  72. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai

  73. Not yet recruiting
    Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07491263

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  74. Not yet recruiting
    U96-CAR-T-Cells For R/R B-ALL
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07511426

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  75. Not yet recruiting
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07539610

    Age 18 years to 69 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  76. Not yet recruiting
    Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
    Phase
    Early phase 1
    Started
    2026-08
    Registry
    NCT07696481

    Age 3 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  77. Not yet recruiting
    SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2026-09
    Registry
    NCT07830238

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  78. Not yet recruiting
    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07840976

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  79. Not yet recruiting
    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07919470

    Age 14 years to 65 years (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang

  80. Not yet recruiting
    Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06861348

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  81. Not yet recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06902025

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  82. Not yet recruiting
    A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07043218

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalShanghai

  83. Not yet recruiting
    Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07087847

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  84. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  85. Not yet recruiting
    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07234045

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  86. Not yet recruiting
    BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07301138

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  87. Not yet recruiting
    Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06559644

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  88. Not yet recruiting
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06641024

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  89. Not yet recruiting
    CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
    Phase
    Early phase 1
    Started
    2020-11
    Registry
    NCT04609241

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions